Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - In order to protect against the further erosion of shareholder value, a group of shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (the "Company"), including two directors, Anthony Durkacz and Zeeshan Saeed, have called a special meeting of the Company's shareholders to be held on March 31, 2021.

As acknowledged by the Company in its January 22, 2021 and January 26, 2021 press releases, on January 4, 2021, shareholders holding more than five percent of the issued shares of the Company carrying the right to vote at a shareholders' meeting requisitioned the Company's directors to call a special meeting of shareholders to be held not later than March 15, 2021. The purpose of the requisitioned meeting is to replace all of the members of the Company's board of directors other than Messrs. Durkacz and Saeed. The additional nominees to the Company's board of directors are Messrs. Larry Latowsky, Fernando Cugliari and Nitin Kaushal, all of whom are well-qualified to serve in this capacity. Additional details about the background and extensive qualifications of these nominees will be provided to shareholders in an information circular prior to the meeting.

In response, the Company's board of directors (other than Messrs. Durkacz and Saeed) has attempted to frustrate the fundamental rights of shareholders to requisition a meeting, by scheduling a meeting to be held nearly six months after the date of the requisition. The board's delay in holding a meeting is a transparent attempt to prevent shareholders from exercising their statutory right to a timely meeting to consider replacement of the current board members. The Company's board is simply trying to frustrate shareholder democracy and deny shareholders their statutory rights.

The Concerned Shareholders are seeking to address the Company's dramatic decline and the staggering loss of shareholder value. Since February 6, 2019, the date of the appointment of Dr. Raza Bokhari as the Company's Chief Executive Officer, the Company's share price has dropped from C$67.33 to C$2.50 as of the close of business today. This decline of over 95% has resulted in the loss of over C$400 million in shareholder value. The Concerned Shareholders believe that change is urgently needed to address this situation, as the Company's management and board of directors have failed to develop an effective strategy for reversing the Company's decline.

In the past weeks, Dr. Bokhari has disregarded numerous requests from the Concerned Shareholders for access to corporate records. Those requests were made in order to investigate apparent irregularities in the Company's governance that have come to the attention of the Concerned Shareholders. For its part, the Company's board of directors has failed to respond to two separate requests for board meetings submitted by Messrs. Durkacz and Saeed. Instead, Dr. Bokhari has sought to wrongfully terminate Mr. Saeed's employment as the Company's President. The Concerned Shareholders have also been informed that at the Company's most recent board meeting, the directors (other than Messrs. Durkacz and Saeed) authorized a large increase in their annual compensation that is wholly inconsistent with the Company's circumstances, performance and the loss of shareholder value during their tenure. This compensation increase was not disclosed in the Company's January 26, 2021 press release.